{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:31:34Z","timestamp":1786987894950,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"DOI":"10.7759\/cureus.114673","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:49:08Z","timestamp":1786985348000},"source":"Crossref","is-referenced-by-count":0,"title":["Zuranolone in Postpartum Depression: Mechanistic Innovation, Clinical Evidence, and Translational Uncertainty"],"prefix":"10.7759","author":[{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Guillermo","family":"Herrera-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gonz\u00e1lez-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeaustin","family":"Mora-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Mill\u00e1n Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01663-6","article-title":"Mapping global prevalence of depression among postpartum women","volume":"11","author":"Wang Z","year":"2021","unstructured":"Wang Z, Liu J, Shuai H, et al.. Mapping global prevalence of depression among postpartum women. Transl Psychiatry. 2021, 11:543. 10.1038\/s41398-021-01663-6","journal-title":"Transl Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","article-title":"Diagnostic and Statistical Manual of Mental Disorders. DSM-5-TR","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-5-TR. American Psychiatric Association Publishing, Washington, DC; 2013. 10.1176\/appi.books.9780890425787"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1607649","article-title":"Postpartum depression","volume":"375","author":"Stewart DE","year":"2016","unstructured":"Stewart DE, Vigod S. Postpartum depression. N Engl J Med. 2016, 375:2177-86. 10.1056\/NEJMcp1607649","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005202","article-title":"Treatment and management of mental health conditions during pregnancy and postpartum: ACOG Clinical Practice Guideline No. 5","volume":"141","year":"2023","unstructured":"Treatment and management of mental health conditions during pregnancy and postpartum. ACOG Clinical Practice Guideline No. 5. Obstet Gynecol. 2023, 141:1262-88. 10.1097\/AOG.0000000000005202","journal-title":"Obstet Gynecol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1745506519844044","article-title":"Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes","volume":"15","author":"Slomian J","year":"2019","unstructured":"Slomian J, Honvo G, Emonts P, Reginster JY, Bruy\u00e8re O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health (Lond). 2019, 15:1745506519844044. 10.1177\/1745506519844044","journal-title":"Womens Health (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ijop.70063","article-title":"A systematic review of the effect of socioeconomic status on the prevalence of postpartum depression (PPD)","volume":"60","author":"Cooke A","year":"2025","unstructured":"Cooke A, Nasiri N, Jayakumar SA, Rangrej SB. A systematic review of the effect of socioeconomic status on the prevalence of postpartum depression (PPD). Int J Psychol. 2025, 60:e70063. 10.1002\/ijop.70063","journal-title":"Int J Psychol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013560.pub2","article-title":"Antidepressant treatment for postnatal depression","volume":"2","author":"Brown JV","year":"2021","unstructured":"Brown JV, Wilson CA, Ayre K, et al.. Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev. 2021, 2:CD013560. 10.1002\/14651858.CD013560.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody S","year":"2018","unstructured":"Meltzer-Brody S, Colquhoun H, Riesenberg R, et al.. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018, 392:1058-70. 10.1016\/S0140-6736(18)31551-4","journal-title":"Lancet"},{"key":"ref9","unstructured":"DailyMed. Zurzuvae (zuranolone) capsule. National Library of Medicine. (2026). Accessed: July 8, 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f18e53b0-d0bb-422d-8de7-ab64b7292b29."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator","volume":"181","author":"Althaus AL","year":"2020","unstructured":"Althaus AL, Ackley MA, Belfort GM, et al.. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. Neuropharmacology. 2020, 181:108333. 10.1016\/j.neuropharm.2020.108333","journal-title":"Neuropharmacology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2018.12.001","article-title":"Pathophysiological mechanisms implicated in postpartum depression","volume":"52","author":"Payne JL","year":"2019","unstructured":"Payne JL, Maguire J. Pathophysiological mechanisms implicated in postpartum depression. Front Neuroendocrinol. 2019, 52:165-80. 10.1016\/j.yfrne.2018.12.001","journal-title":"Front Neuroendocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial","volume":"78","author":"Deligiannidis KM","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al.. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 2021, 78:951-9. 10.1001\/jamapsychiatry.2021.1559","journal-title":"JAMA Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis KM","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, et al.. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023, 180:668-75. 10.1176\/appi.ajp.20220785","journal-title":"Am J Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"U.S. Food and Drug Administration. FDA approves first oral treatment for postpartum depression. (2024). Accessed: July 8, 2026: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-treatment-postpartum-depression.","DOI":"10.1002\/cpu.30811"},{"key":"ref15","unstructured":"Biogen. FDA Approves Zurzuvae\u2122 (zuranolone), the first and only oral treatment approved for women with postpartum depression. (2023). Accessed: July 8, 2026: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-approves-zurzuvaetm-zuranolone-first-and-only-ora...."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-3467(07)60142-6","article-title":"Writing narrative literature reviews for peer-reviewed journals: secrets of the trade","volume":"5","author":"Green BN","year":"2006","unstructured":"Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006, 5:101-17. 10.1016\/S0899-3467(07)60142-6","journal-title":"J Chiropr Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000006093","article-title":"Zuranolone and brexanolone for the treatment of postpartum depression","volume":"147","year":"2026","unstructured":"Zuranolone and brexanolone for the treatment of postpartum depression. Obstet Gynecol. 2026, 147.e24-8. 10.1097\/AOG.0000000000006093","journal-title":"Obstet Gynecol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.06.019","article-title":"GABA(A)R plasticity during pregnancy: relevance to postpartum depression","volume":"59","author":"Maguire J","year":"2008","unstructured":"Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008, 59:207-13. 10.1016\/j.neuron.2008.06.019","journal-title":"Neuron"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014624.pub2","article-title":"Brexanolone, zuranolone and related neurosteroid GABA(A) receptor positive allosteric modulators for postnatal depression","volume":"6","author":"Wilson CA","year":"2025","unstructured":"Wilson CA, Robertson L, Ayre K, Hendon JL, Dawson S, Bridges C, Khalifeh H. Brexanolone, zuranolone and related neurosteroid GABA(A) receptor positive allosteric modulators for postnatal depression. Cochrane Database Syst Rev. 2025, 6:CD014624. 10.1002\/14651858.CD014624.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14475","article-title":"Effect of zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression","volume":"84","author":"Deligiannidis KM","year":"2023","unstructured":"Deligiannidis KM, Citrome L, Huang MY, et al.. Effect of zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression. J Clin Psychiatry. 2023, 84:22m14475. 10.4088\/JCP.22m14475","journal-title":"J Clin Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-022-01333-4","article-title":"Perinatal obsessive-compulsive disorder: epidemiology, phenomenology, etiology, and treatment","volume":"24","author":"Hudepohl N","year":"2022","unstructured":"Hudepohl N, MacLean JV, Osborne LM. Perinatal obsessive-compulsive disorder: epidemiology, phenomenology, etiology, and treatment. Curr Psychiatry Rep. 2022, 24:229-37. 10.1007\/s11920-022-01333-4","journal-title":"Curr Psychiatry Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001873","article-title":"Zuranolone concentrations in the breast milk of healthy, lactating individuals: results from a phase 1 open-label study","volume":"44","author":"Deligiannidis KM","year":"2024","unstructured":"Deligiannidis KM, Bullock A, Nandy I, et al.. Zuranolone concentrations in the breast milk of healthy, lactating individuals: results from a phase 1 open-label study. J Clin Psychopharmacol. 2024, 44:337-44. 10.1097\/JCP.0000000000001873","journal-title":"J Clin Psychopharmacol"},{"key":"ref24","unstructured":"Zuranolone. In. Drugs and Lactation Database (LactMed\u00ae). National Library of Medicine. (2006). (2006). Accessed: July 9, 2026: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK594292\/."},{"key":"ref25","unstructured":"European Medicines Agency. Zurzuvae. (2025). Accessed: July 8, 2026: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zurzuvae."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2334160","article-title":"Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression","volume":"27","author":"Meltzer-Brody S","year":"2024","unstructured":"Meltzer-Brody S, Gerbasi ME, Mak C, et al.. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression. J Med Econ. 2024, 27:582-95. 10.1080\/13696998.2024.2334160","journal-title":"J Med Econ"},{"key":"ref27","article-title":"Zuranolone (Zurzuvae) for the treatment of postpartum depression","volume":"111","author":"Montgomery J","year":"2025","unstructured":"Montgomery J, Hoffman A. Zuranolone (Zurzuvae) for the treatment of postpartum depression. Am Fam Physician. 2025, 111:465-6.","journal-title":"Am Fam Physician"},{"key":"ref28","unstructured":"WHO guideline on country pharmaceutical pricing policies. (2020). Accessed. August 8, 2026: https:\/\/www.who.int\/publications\/i\/item\/9789240011878."},{"key":"ref29","unstructured":"WHO guide for integration of perinatal mental health in maternal and child health services. (2022). Accessed. August 08, 2026: https:\/\/www.who.int\/publications\/i\/item\/9789240057142."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-024-06735-1","article-title":"Breastfeeding experiences of women with perinatal mental health problems: a systematic review and thematic synthesis","volume":"24","author":"Billings H","year":"2024","unstructured":"Billings H, Horsman J, Soltani H, Spencer RL. Breastfeeding experiences of women with perinatal mental health problems: a systematic review and thematic synthesis. BMC Pregnancy Childbirth. 2024, 24:582. 10.1186\/s12884-024-06735-1","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512234-zuranolone-in-postpartum-depression-mechanistic-innovation-clinical-evidence-and-translational-uncertainty","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:49:10Z","timestamp":1786985350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512234-zuranolone-in-postpartum-depression-mechanistic-innovation-clinical-evidence-and-translational-uncertainty"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.114673","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}